Matthew R. Henn, See Remarks at Seres Therapeutics, Inc. (MCRB), sold 81 shares at $4.55 ($369) on 2026-08-17, disclosed to the SEC on 2026-08-18.
Scheduled sale ($369) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| MCRB | SELL | 2025-11-18 | $22K | — | Filing → |
| MCRB | SELL | 2025-08-19 | $1K | — | Filing → |
| MCRB | SELL | 2025-05-19 | $561 | — | Filing → |